Comparison of Effects of Atorvastatin (20 mg) Versus Rosuvastatin (10 mg) Therapy on Mild Coronary Atherosclerotic Plaques (from the ARTMAP Trial)

详细信息	查看全文 | 推荐本文 |

• 作者：Cheol Whan Lee ; MD ; Su-Jin Kang ; MD ; Jung-Min Ahn ; MD ; Hae Geun Song ; MD ; Jong-Young Lee ; MD ; Won-Jang Kim ; MD ; Duk-Woo Park ; MD ; Seung-Whan Lee ; MD ; Young-Hak Kim ; MD ; Seong-Wook Park ; MD ; PhD ; Seung-Jung Park ; MD ; PhD ; ^{sjpark@amc.seoul.kr}
• 刊名：The American Journal of Cardiology
• 出版年：2012
• 期刊代码：5_00029149
• 类别：med
• 出版时间：15 June, 2012
• 卷：109
• 期：12
• 页码：1700-1704
• 文件大小：390 K

摘要

High-dose rosuvastatin induces regression of coronary atherosclerosis, but it remains uncertain whether usual-dose statin has similar effects. We compared the effects of atorvastatin 20 mg/day versus rosuvastatin 10 mg/day on mild coronary atherosclerotic plaques (20%to 50%luminal narrowing and lesion length >10 mm) using intravascular ultrasound (IVUS). Three hundred fifty statin-naive patients with mild coronary atherosclerotic plaques were randomized to receive atorvastatin 20 mg/day or rosuvastatin 10 mg/day. IVUS examinations were performed at baseline and 6-month follow-up. Primary end point was percent change in total atheroma volume (TAV) defined as (TAV at 6 months 鈭?TAV at baseline)/(TAV at baseline) 脳 100. Evaluable IVUS was obtained for 271 patients (atorvastatin in 143, rosuvastatin in 128). Clinical characteristics, lipid levels, and IVUS measurements at baseline were similar between the 2 groups. At 6-month follow-up, percent change in TAV was significantly less in the atorvastatin group than in the rosuvastatin group (鈭?.9 卤 11.9%vs 鈭?.4 卤 10.6%, respectively, p = 0.018). In contrast, change in percent atheroma volume was not different between the 2 groups (鈭?.3 卤 4.2 vs 鈭?.1 卤 3.5, respectively, p = 0.157). Compared to baseline, TAV and TAV at the most diseased 10-mm subsegment were significantly decreased in the 2 groups (p <0.001). Changes in lipid profiles at 6-month follow-up were similar between the 2 groups. In conclusion, usual doses of atorvastatin and rosuvastatin induced significant regression of coronary atherosclerosis in statin-naive patients, with a greater decrease in favor of rosuvastatin.